Neuroretinitis and intracranial venous thrombosis in antiphospholipid syndrome

Molina, J. Pelegrina; Hernández, Francisco Javier Barrero; Rubio, José Luis Callejas; Alaminos, R. Anaya; Centeno, Norberto Ortego

doi:10.1016/j.nrleng.2012.10.007

Cited by 1 publication

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Shlebak 128 IgG Transverse sinus, sigmoid sinus Warfarin Shlebak 128 IgG Transverse sinus Warfarin Behrendt et al 129 IgM and IgG Superior sagittal sinus, right transverse sinus Warfarin, venticuloperitoneal shunt Pelegrina Molina et al 130 IgG Superior sagittal sinus, right transverse sinus Warfarin, corticosteroids Nagai et al 131 Unspecified Superior sagittal sinus, cortical vein Corticosteroids Miki et al 132 Unspecified Straight sinus Anticoagulation Ikejiri et al 133 IgG Right transverse sinus NR Numata et al 134 Unspecified Cortical vein Therapeutic heparin Hsieh et al 135 IgM Superior sagittal sinus, right transverse sinus Warfarin, corticosteroids Sakamoto et al 136 Unspecified Superior sagittal sinus Warfarin brain small vessels leading to inflammatory vascular occlusion. 79 Despite that SLE is characterized by low complement levels, elevated complement levels were associated with stroke.…”

Section: Reference Antibody Subtype Vein Treatmentmentioning

confidence: 99%

Lupus, antiphospholipid syndrome, and stroke: An attempt to crossmatch

Hasbani

Uthman

2023

Lupus

View full text Add to dashboard Cite

Cerebrovascular accidents (CVAs) or strokes are part of the common thrombotic manifestations of Systemic Lupus Erythematosus (SLEs) and Antiphospholipid syndrome (APS). Such neurological thrombotic events tend to occur in patients with SLE at a higher frequency when Antiphospholipid antibodies (aPLs) are present, and tend to involve the large cerebral vessels. The mechanism of stroke in SLE can be driven by complement deposition and neuroinflammation involving the blood–brain barrier although the traditional cardiovascular risk factors remain major contributing factors. Primary prevention with antiplatelet therapy and disease activity controlling agent is the basis of the management. Anticoagulation via warfarin had been a tool for secondary prevention, especially in stroke recurrence, although the debate continues regarding the target international normalized ratio (INR). The presence of either of the three criteria antiphospholipid antibodies (aPLs) and certain non-criteria aPL can be an independent risk factor for stroke. The exact mechanism for the involvement of the large cerebral arteries, especially in lupus anticoagulant (LAC) positive cases, is still to be deciphered. The data on the role of non-criteria aPL remain very limited and heterogenous, but IgA antibodies against β2GPI and the D4/5 subunit as well as aPS/PT IgG might have a contribution. Anticoagulation with warfarin has been recommended although the optimal dosing or the utility of combination with antiplatelet agents is still unknown. Minimal data is available for direct oral anticoagulants (DOACs).

show abstract